BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klenerman P, Fitzmaurice K. An update on hepatitis C virus. Clin Med (Lond) 2015;15 Suppl 6:s33-6. [PMID: 26634679 DOI: 10.7861/clinmedicine.15-6-s33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Younossi ZM, Stepanova M, Charlton M, Curry MP, O'Leary JG, Brown RS, Hunt S. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 2016;1:122-32. [PMID: 28404069 DOI: 10.1016/S2468-1253(16)30009-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 11] [Article Influence: 8.2] [Reference Citation Analysis]
2 Xie Q, Chen S, Tian R, Huang X, Deng R, Xue B, Qin Y, Xu Y, Wang J, Guo M, Chen J, Tang S, Li G, Zhu H. Long Noncoding RNA ITPRIP-1 Positively Regulates the Innate Immune Response through Promotion of Oligomerization and Activation of MDA5. J Virol 2018;92:e00507-18. [PMID: 29899107 DOI: 10.1128/JVI.00507-18] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]